SRPK1 contributes to malignancy of hepatocellular carcinoma through a possible mechanism involving PI3K/Akt.
about
Splicing Regulators and Their Roles in Cancer Biology and TherapySerine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancerBoth decreased and increased SRPK1 levels promote cancer by interfering with PHLPP-mediated dephosphorylation of Akt.MicroRNA-1296 inhibits metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting SRPK1-mediated PI3K/AKT pathway.Elevated SRPK1 lessens apoptosis in breast cancer cells through RBM4-regulated splicing events.Serine-arginine protein kinase 1 promotes a cancer stem cell-like phenotype through activation of Wnt/β-catenin signalling in NSCLC.SRPK1 Dissimilarly Impacts on the Growth, Metastasis, Chemosensitivity and Angiogenesis of Glioma in Normoxic and Hypoxic Conditions.Pharmacology of Modulators of Alternative Splicing.Plexin-B1 indirectly affects glioma invasiveness and angiogenesis by regulating the RhoA/αvβ3 signaling pathway and SRPK1.Up-regulation of SRPK1 in non-small cell lung cancer promotes the growth and migration of cancer cells.The crucial role of SRPK1 in TGF-β-induced proliferation and apoptosis in the esophageal squamous cell carcinomas.The influence of SRPK1 on glioma apoptosis, metastasis, and angiogenesis through the PI3K/Akt signaling pathway under normoxia.Catalpol Inhibited the Proliferation of T24 Human Bladder Cancer Cells by Inducing Apoptosis Through the Blockade of Akt-Mediated Anti-apoptotic Signaling.Serine-arginine protein kinase 1 is associated with breast cancer progression and poor patient survival.Von Hippel-Lindau status influences phenotype of liver cancers arising from PTEN loss.SRPK1 inhibition in prostate cancer: A novel anti-angiogenic treatment through modulation of VEGF alternative splicing.Serine-arginine protein kinase 1 (SRPK1) is elevated in gastric cancer and plays oncogenic functionsG2/M checkpoint plays a vital role at the early stage of HCC by analysis of key pathways and genes.Downregulation and tumor-suppressive role of XPO5 in hepatocellular carcinoma.Expression of SRPK1 in gliomas and its role in glioma cell lines viability.The Critical Role of SRPK1 in EMT of Human Glioblastoma in the Spinal Cord.
P2860
Q26798158-787F5B2D-8381-4AA9-AEF8-B3E95A5B5171Q28251240-4D39A463-C765-42B5-B845-C0BE8650D457Q33605329-5F6AC75D-C091-40AB-9D34-341444EF9BFEQ33792251-4FD2F238-C6B7-4F70-BAF7-CD6DE06B3B99Q34240895-59356B62-C1D9-46F2-9DAB-27447AA8A313Q36071281-17860020-F065-408E-9819-5D60F4C549EBQ37347529-83663FCE-0644-48A0-967F-D4534D0C9D8DQ38776406-239C42F9-514B-40F2-A9A6-DFD82A404B16Q38788887-DF5D2BB6-D646-450E-A1CF-6164A2D13618Q38811803-A4706BD4-5FDF-4560-B0EE-31081F313D9AQ38861204-98D92D05-F5A0-4284-A4F2-FA785B8DEFCCQ38891990-897ECA88-9F48-4B0E-80E9-4EE96FDA1A56Q38941125-8BAC9A69-E25D-4083-BA48-7054FBD9BDC4Q38981645-8B8523FF-61D2-4FCA-921C-29C18DB02009Q41113380-5EC431D6-D8C8-4EDE-A37F-D5A05744B445Q41858027-E0943F16-1D55-4755-A0F7-D5BF72BB76C1Q42365311-A2EE4EF7-9B4F-4F37-8AF3-F4A76620C320Q47129957-DFC65BD8-B9FB-492A-A360-5683BBC0759BQ53141136-D72270B8-2FC0-4376-8E3C-AA292BCBF54DQ53221473-25126226-B218-474E-8029-1A8022C0EEBAQ55030693-E0EF4B7D-FE75-4833-8DDA-213676DD80DD
P2860
SRPK1 contributes to malignancy of hepatocellular carcinoma through a possible mechanism involving PI3K/Akt.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
SRPK1 contributes to malignanc ...... mechanism involving PI3K/Akt.
@en
SRPK1 contributes to malignanc ...... mechanism involving PI3K/Akt.
@nl
type
label
SRPK1 contributes to malignanc ...... mechanism involving PI3K/Akt.
@en
SRPK1 contributes to malignanc ...... mechanism involving PI3K/Akt.
@nl
prefLabel
SRPK1 contributes to malignanc ...... mechanism involving PI3K/Akt.
@en
SRPK1 contributes to malignanc ...... mechanism involving PI3K/Akt.
@nl
P2093
P2860
P1476
SRPK1 contributes to malignanc ...... e mechanism involving PI3K/Akt
@en
P2093
P2860
P2888
P304
P356
10.1007/S11010-013-1641-7
P50
P577
2013-05-06T00:00:00Z